Technology
Health
Biotechnology

Cellect Biotechnology

$1.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0787 (-7.36%) Today
+$0.02 (1.89%) After Hours

Why Robinhood?

You can buy or sell APOP and other stocks, options, ETFs, and crypto commission-free!

About

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. Read More The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Employees
28
Headquarters
Kfar Saba, Jerusalem
Founded
1986
Market Cap
6.46M
Price-Earnings Ratio
Dividend Yield
Average Volume
98.32K
High Today
$1.07
Low Today
$0.98
Open Price
$1.07
Volume
199.54K
52 Week High
$7.85
52 Week Low
$0.9301

Collections

Technology
Health
Biotechnology
Medical
2016 IPO
Asia (Non-China)
Asia

News

PR NewswireMar 18

Cellect Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress

TEL AVIV, Israel, March 18, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2018, as well as recent corporate progress. "We made progress in 2018 as we overcame the short-term setback of patient recruitment in our trial in Israel and moved closer to the initiation of our U.S. clinical efforts," commented Dr. Shai Yarkoni, Chief Execu...

49
StreetInsiderMar 11

Cellect Biotechnology (APOP) Announces Positive Results From Cell2in Collaboration

Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced positive preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells. Results of this third-party study further validate that Cellect's Apograft™ technology significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow, pe...

39
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.